

Clinical Pharmacy Program Guidelines for Crestor

Program	Prior Authorization
Medication	Crestor (rosuvastatin)
Issue Date	6/2015
Pharmacy and Therapeutics Approval Date	7/2017
Effective Date	9/2017

1. Background:

Indications

Crestor is an HMG Co-A reductase inhibitor indicated for:

- Patients with primary hyperlipidemia and mixed dyslipidemia as an adjunct to diet to reduce elevated total-C, LDL-C, ApoB, nonHDL-C, and TG levels and to increase HDL-C
- Patients with hypertriglyceridemia as an adjunct to diet
- Patients with primary dysbetalipoproteinemia (Type III hyperlipoproteinemia) as an adjunct to diet
- Patients with homozygous familial hypercholesterolemia (HoFH) to reduce LDL-C, total-C, and ApoB
- Slowing the progression of atherosclerosis as part of a treatment strategy to lower total-C and LDL-C as an adjunct to diet
- Pediatric patients 8 to 17 years of age with heterozygous familial hypercholesterolemia (HeFH) to reduce elevated total-C, LDL-C and ApoB after failing an adequate trial of diet therapy
- Pediatric patients 7 to 17 years of age with homozygous familial hypercholesterolemia (HoFH) to reduce LDL-C, total-C, nonHDL-C and ApoB as an adjunct to diet, either alone or with other lipid-lowering treatments
- Risk reduction of MI, stroke, and arterial revascularization procedures in patients without clinically evident CHD, but with multiple risk factors

Limitations of use:

- Crestor has not been studied in Fredrickson Type I and V dyslipidemias.

2. Coverage Criteria:

<p>A. <u>Initial Authorization</u></p> <p>1. <u>One</u> of the following:</p>
--

a. History of failure to at least a 90 day trial of atorvastatin 80mg daily

OR

b. History of failure, intolerance, or contraindication to **ALL** of the following:

- Atorvastatin
- Lovastatin
- Simvastatin

Authorization will be issued for 12 months.

3. References:

1. Crestor [package insert]. Wilmington, DE: AstraZeneca; May 2016.
2. Stone NJ, Robinson J, Lichtenstein AH et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. *Circulation*. 2013.

Program	Program type -
Change Control	
Date	Change
6/18/2015	New policy
10/2016	Annual review. Updated policy template.
7/2017	Updated background and preferred alternative language.